Achieve Life Sciences (NASDAQ:ACHV) is a clinical‐stage biopharmaceutical company focused on developing therapies to help people overcome nicotine addiction. The company’s lead compound, cytisinicline, is a plant‐derived alkaloid that acts as a partial agonist at nicotinic acetylcholine receptors, and has shown promise in supporting smoking cessation without the side effects commonly associated with other pharmacotherapies. Achieve is advancing cytisinicline through global regulatory pathways, with pivotal Phase 3 trials underway in the United States and Canada, and preparations for regulatory submissions in key markets.
The company’s research and development efforts center on demonstrating the safety, tolerability and efficacy of cytisinicline in comparison to existing smoking‐cessation products. Achieve has reported positive interim data indicating high rates of continuous abstinence three months after treatment initiation, with a favorable safety profile. In addition to its own development programs, the company is exploring combination approaches and new dosage forms to optimize patient adherence and outcomes.
Achieve Life Sciences holds a diversified portfolio of licensing partnerships to support commercialization of cytisinicline worldwide. Under a licensing agreement with a leading European pharmaceutical firm, Achieve granted exclusive rights to market cytisinicline in several European Union countries, while retaining development and commercialization rights in North America and select Asia‐Pacific territories. The company is actively engaging with regulatory authorities and strategic partners to expand access to its product in markets where smoking remains a leading cause of preventable disease.
Founded through the rebranding of Filament Biosciences in 2018, Achieve Life Sciences is headquartered in Vancouver, Canada, with research and clinical operations in North America. The company’s management team comprises seasoned executives with deep expertise in clinical development, regulatory affairs and pharmaceutical commercialization. Under their leadership, Achieve aims to bring a novel, evidence‐based solution to the global challenge of tobacco dependence.
